Ultomiris shows sustained gMG improvements at 60 weeks

The latest results from the Phase III CHAMPION-MG trial open-label extension showed that Ultomiris (ravulizumab-cwvz) demonstrated long-term efficacy in adults with anti-acetylcholine receptor (AChR) antibody-positive generalised myasthenia gravis (gMG).

There were improvements in activities of daily living, muscle strength and quality of life, sustained through 60 weeks, the results showed, and the long-acting C5 complement inhibitor was also well tolerated throughout the analysis.

Patients who transitioned from placebo to Ultomiris showed rapid and sustained response, reinforcing clinical benefit of C5 inhibition.